ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc (OTCQX:ANPCY) announced it will present on the Investor Meet Company platform at 11:00 am (BST) on April 28, 2023. The session will feature insights from CEO Andrew Newland and CFO Ian Griffiths, focusing on the company's strategic activities. Investors have the opportunity to submit questions until April 26, 2023, that will be addressed during the presentation. ANGLE is known for its Parsortix system, the first FDA-cleared device for harvesting intact circulating tumor cells (CTCs) from blood, primarily for metastatic breast cancer. The technology shows promising clinical results in ongoing studies, demonstrating high accuracy in cancer detection and analysis. For details and registration, investors can visit the provided link.

ANGLE plc (OTCQX:ANPCY) reported significant milestones in its 2022 financial results, marking a breakthrough year with FDA clearance for the Parsortix PC1 Clinical System. This system allows for the harvesting of intact cancer cells from blood samples, a first in its class. The company achieved revenue of £1.0 million in 2022, consistent with 2021, while losses rose to £21.7 million due to planned investments. An encouraging performance in Q1 2023 reported strong year-on-year revenue growth. A major partnership with Solaris Health focuses on prostate cancer, and additional contracts with pharma clients highlight increasing demand for its services. ANGLE's healthy cash position stands at £31.9 million, complemented by ongoing R&D Tax Credits, setting a solid foundation for growth.

ANGLE plc has announced a development partnership with BioView Ltd. to create a circulating tumor cell (CTC) HER2 assay for breast cancer. This collaboration utilizes ANGLE's FDA-cleared Parsortix PC1 Clinical System and BioView's microscopy technology. The first phase is projected to generate approximately £1.2 million in revenue. As breast cancer treatment evolves, there is a significant opportunity to develop a quantitative HER2 assay that can monitor patients' HER2 status over time. The HER2-low breast cancer segment, accounting for 55% of breast cancer cases, is gaining attention, especially with the introduction of targeted therapies like ENHERTU. Analysts anticipate a potential US$3 billion annual increase in sales value due to this market expansion.